31,122 results match your criteria Graft Versus Host Disease


Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.

Mol Ther 2019 Apr 8. Epub 2019 Apr 8.

Allogene Therapeutics, Inc., 210 E. Grand Avenue, South San Francisco, CA 94080, USA. Electronic address:

Clinical success of autologous CD19-directed chimeric antigen receptor T cells (CAR Ts) in acute lymphoblastic leukemia and non-Hodgkin lymphoma suggests that CAR Ts may be a promising therapy for hematological malignancies, including multiple myeloma. However, autologous CAR T therapies have limitations that may impact clinical use, including lengthy vein-to-vein time and manufacturing constraints. Allogeneic CAR T (AlloCAR T) therapies may overcome these innate limitations of autologous CAR T therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ymthe.2019.04.001DOI Listing

Vaccination of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient.

Infect Dis Clin North Am 2019 Jun;33(2):593-609

Infectious Disease Service, Department of Medicine, Weill Cornell Medical College, 275 York Avenue, Box 420, New York, NY 10065, USA.

Patients with hematologic malignancy or those who undergo hematopoietic stem cell transplantation experience variable degrees of immunosuppression, dependent on underlying disease, therapy received, time since transplant, and complications, such as graft-versus-host disease. Vaccination is an important strategy to mitigate onset and severity of certain vaccine-preventable illnesses, such as influenza, pneumococcal disease, or varicella zoster infection, among others. This article highlights vaccines that should and should not be used in this patient population and includes general guidelines for timing of vaccination administration and special considerations in the context of newer therapies, recent vaccine developments, travel, and considerations for household contacts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.idc.2019.02.007DOI Listing

Clostridioides difficile Infection in the Stem Cell Transplant and Hematologic Malignancy Population.

Infect Dis Clin North Am 2019 Jun;33(2):447-466

Department of Medicine, Division of Infectious Disease, University of Wisconsin School of Medicine & Public Health, 1685 Highland Drive, Centennial Building, 5th Floor, Madison, WI 53705, USA; Department of Medicine, William S. Middleton Memorial Veterans Hospital, Madison, WI 53705, USA.

Clostridioides difficile infection (CDI) is common in the stem cell transplant (SCT) and hematologic malignancy (HM) population and mostly occurs in the early posttransplant period. Treatment of CDI in SCT/HM is the same as for the general population, with the exception that fecal microbiota transplant (FMT) has not been widely adopted because of safety concerns. Several case reports, small series, and retrospective studies have shown that FMT is effective and safe. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.idc.2019.02.010DOI Listing

Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia.

Transpl Infect Dis 2019 Apr 20:e13096. Epub 2019 Apr 20.

Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taiwan.

Background: Owing to the shortage of hematopoietic stem cells from matched sibling donors (MSD) and matched unrelated donors (MUD), the number of patients undergoing haploidentical allogeneic hematopoietic stem cell transplantation (allo-HSCT) has rapidly increased. Despite a comparable overall survival (OS) and leukemia-free survival using this approach, some evidence suggests that haploidentical allo-HSCT recipients have a higher incidence of cytomegalovirus (CMV) infection, though this has not been clearly established.

Methods: This study retrospectively compared the cumulative incidence of CMV DNAemia, 2-year OS, and leukemia-free survival rates in acute leukemia patients with with MSD (n=41), MUD (n=18), and haploidentical donor allografts (n=21). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/tid.13096DOI Listing

Lung clearance index for early detection of pulmonary complications after allo-HSCT in children.

Pediatr Pulmonol 2019 Apr 19. Epub 2019 Apr 19.

Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Background: Pulmonary chronic graft-vs-host disease (cGvHD) after hematopoietic stem cell transplantation (HSCT) is characterized by impairment of the small airways. Assessment of lung clearance index (LCI) gained from multiple breath washout (MBW) is more sensitive than spirometry in detection of small airways disease. The aim of this study was to describe the development of LCI during the first year after pediatric HSCT and how LCI relates to other pulmonary function parameters and cGvHD. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/ppul.24340
Publisher Site
http://dx.doi.org/10.1002/ppul.24340DOI Listing
April 2019
2 Reads

Blinatumomab for Acute Lymphoblastic Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.

Biol Blood Marrow Transplant 2019 Apr 16. Epub 2019 Apr 16.

Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.

Patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) following allogeneic hematopoietic stem cell transplantation (alloHSCT) have a poor prognosis, and alternative therapies are needed for this patient population. Blinatumomab, a bispecific T-cell engager immunotherapy, was evaluated in an open-label, single-arm, phase 2 study of adults with R/R Philadelphia chromosomenegative B-cell precursor ALL and resulted in a complete remission (CR) or CR with partial hematologic recovery of peripheral blood counts (CRh) rate of 43% within 2 treatment cycles. We conducted an exploratory analysis to determine the efficacy and safety of blinatumomab in 64 patients who had relapsed following alloHSCT prior to enrollment in the phase 2 study. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791193023
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2019.04.010DOI Listing
April 2019
1 Read

Incidence and outcomes of bacterial bloodstream infections during acute graft-versus-host disease involving the gastrointestinal tract following hematopoietic-cell transplant.

Biol Blood Marrow Transplant 2019 Apr 16. Epub 2019 Apr 16.

Department of Medicine, Oregon Health and Science University, Portland, OR, USA; Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, USA. Electronic address:

Background: Despite the association of acute graft-versus-host disease (aGVHD) and bacterial bloodstream infections (BSIs) in hematopoietic-cell transplant (HCT) recipients, relatively little is known about BSIs specifically during gastrointestinal (GI) tract aGVHD (aGHVD-GI). The purpose of this study was to evaluate the incidence, risk factors, and mortality of BSIs complicating aGVHD-GI.

Methods: This was a retrospective review of adult HCT recipients with grade I-IV aGVHD-GI between January 2009 and October 2017 at Oregon Health and Sciences University (OHSU). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791193023
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2019.04.016DOI Listing
April 2019
1 Read

Altered donor P2X7 activity in human leukocytes correlates with P2RX7 genotype but does not affect the development of graft-versus-host disease in humanised mice.

Purinergic Signal 2019 Apr 18. Epub 2019 Apr 18.

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW, 2522, Australia.

Graft-versus-host disease (GVHD) is a life-threatening consequence of allogeneic haematopoietic stem cell transplantation, a curative therapy for haematological malignancies. The ATP-gated P2X7 receptor channel is implicated in the development of GVHD. P2X7 activity on human leukocytes can be influenced by gain-of-function (GOF) and loss-of-function (LOF) single nucleotide polymorphisms (SNPs) in the P2RX7 gene. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11302-019-09651-8
Publisher Site
http://dx.doi.org/10.1007/s11302-019-09651-8DOI Listing
April 2019
1 Read

Donor Allospecific CD44 Central Memory T Cells Have Decreased Ability to Mediate Graft-vs.-Host Disease.

Front Immunol 2019 2;10:624. Epub 2019 Apr 2.

Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, United States.

Data from both animal models and humans have demonstrated that effector memory T cells (T) and central memory T cells (T) from unprimed donors have decreased ability to induce graft-vs-host disease (GVHD). Allospecific T from primed donors do not mediate GVHD. However, the potential of alloreactive T to induce GVHD is not clear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00624DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454869PMC

Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model.

Front Immunol 2019 2;10:619. Epub 2019 Apr 2.

Hematology Research Unit, GIGA-I3, GIGA Institute, University of Liège, Liège, Belgium.

Mesenchymal stromal cells (MSCs) have potent immunomodulatory properties that make them an attractive tool against graft- vs.-host disease (GVHD). However, despite promising results in phase I/II studies, bone marrow (BM-) derived MSCs failed to demonstrate their superiority over placebo in the sole phase III trial reported thus far. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2019.00619
Publisher Site
http://dx.doi.org/10.3389/fimmu.2019.00619DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454068PMC
April 2019
2 Reads

[Children and adolescents discharge guidelines after allogeneic stem cell transplantation for healthcare professionals: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Bull Cancer 2019 Apr 15. Epub 2019 Apr 15.

Hôpital Robert-Debré, département d'hémato-immunologie pédiatrique, 48, boulevard Serurier, 75019 Paris, France; Université Paris 7-Paris Diderot, 5, rue Thomas-Mann, 75013 Paris, France. Electronic address:

Recommendations for visits or environment restrictions, and sometimes for food are usually well described for inpatient within HSCT unit procedures where those measures are less precise and detailed for outpatient from the discharge to the immune reconstitution achievement. The present paper main objective is to define risk patient groups depending on time, immune-suppressive drugs as well as graft-versus-host disease and immune reconstitution. We define here 3 risk patient groups and propose measures about house cleaning, pets, schools, social activities, hygiene, foods, sexual life and siblings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.03.006DOI Listing

[Association between IL-10 Gene -592(C→A) (rs1800872) SNP and GVHD after Allogeneic Hematopoietic Stem Cell Transplantation in Children].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):573-579

Hematology Oncology Center of Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology; National Key Discipline of Pediatrics (Capital Medical University); Key Laboratory of Major Diseases in Children, Ministry of Education; Beijing 100045, ChinaE-mail:

Objective: To study the association between IL-10 gene-592(C→A) (rs1800872) single nucleotide polymorphism (SNP) and the graft versus host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children.

Methods: Ninety-seven childhood patients and seventy-one donors in the Hematology Oncology Center of Beijing Children's Hospital from Jan 2011 to Jul 2017 were enrolled in this study. The genomic DNA was extracted from peripheral blood cells and the SNP genotype was analyzed using TaqMan SNP genotyping assay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.043DOI Listing
April 2019
1 Read

Interrater Reliability of Clinical Grading Measures for Cutaneous Chronic Graft-vs-Host Disease.

JAMA Dermatol 2019 Apr 17. Epub 2019 Apr 17.

Department of Dermatology, Duke University, Durham, North Carolina.

Importance: Cutaneous chronic graft-vs-host disease (cGVHD) is common after allogeneic hematopoietic stem cell transplant and is often associated with poor patient outcomes. A reliable and practical method for assessing disease severity and response to therapy among these patients is urgently needed.

Objective: To evaluate the interrater agreement and reliability of skin-specific and range of motion (ROM) variables of the 2014 National Institutes of Health (NIH) response criteria for cGVHD and a skin sclerosis grading scale (SSG). Read More

View Article

Download full-text PDF

Source
http://archderm.jamanetwork.com/article.aspx?doi=10.1001/jam
Publisher Site
http://dx.doi.org/10.1001/jamadermatol.2018.5459DOI Listing
April 2019
2 Reads

Decoding Skin Involvement in Chronic Graft-vs-Host Disease.

Authors:
Edward W Cowen

JAMA Dermatol 2019 Apr 17. Epub 2019 Apr 17.

Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2019.0354DOI Listing
April 2019
1 Read

The benefit of chronic graft-versus-host disease in patients with acute myeloid leukemia relapsed after allogeneic stem cell transplantation.

Ann Hematol 2019 Apr 16. Epub 2019 Apr 16.

Department of Hematology, Changhai Hospital, The Second Military Medical University, Shanghai, China.

To investigate the effect of chronic graft-versus-host disease (cGVHD) on the outcomes of acute myeloid leukemia (AML) patients who relapsed after allogenic hematopoietic cell transplantation, we performed a retrospective analysis on 218 patients with a median follow-up of 21.4 (3.4-179. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03682-2DOI Listing
April 2019
1 Read

Allogeneic donor split skin grafts for treatment of refractory ulcers in cutaneous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation-a retrospective analysis on seven patients.

Ann Hematol 2019 Apr 16. Epub 2019 Apr 16.

Department of Plastic, Reconstructive and Hand Surgery, University Hospital, Regensburg, Germany.

Refractory skin ulcers due to severe chronic graft-versus-host disease (cGVHD) remain to be associated with significant morbidity and mortality.We performed an allogeneic donor skin transplantation in seven adult patients after allogeneic hematopoietic stem cell transplantation for cGVHD-associated refractory skin ulcers. While four patients received a split skin graft (SSG), in one patient, a full thickness skin graft for two small refractory ulcers of the ankle was performed, and one patient received in vitro expanded donor keratinocyte grafts derived from hair roots of the original unrelated donor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03687-xDOI Listing
April 2019
1 Read

Safety of Probiotics Among High-Risk Pediatric Hematopoietic Stem Cell Transplant Recipients.

Infect Dis Ther 2019 Apr 15. Epub 2019 Apr 15.

Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA.

Introduction: Increased diversity of the intestinal microbiome has been significantly associated with lower mortality after hematopoietic stem cell transplant (HSCT). Probiotics, such as Lactobacillus species with defined probiotic potential, may have beneficial properties including restoration of commensal species to the intestinal tract, anti-microbial effects, and healing of the intestinal mucosa. However, the use of probiotics in immune-compromised patients raises concerns, specifically regarding the risk for possible Lactobacillus bacteremia. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40121-019-0244-3
Publisher Site
http://dx.doi.org/10.1007/s40121-019-0244-3DOI Listing
April 2019
2 Reads

T Regulatory Cells in Donor Grafts May Predict the Severity of Acute Graft Versus Host Disease After Matched Sibling Donor Allogenic Peripheral Blood Stem Cell Transplantation.

Indian J Hematol Blood Transfus 2019 Apr 7;35(2):233-239. Epub 2019 Jan 7.

2Department of Hematology, All India Institute of Medical Sciences (AIIMS), New Delhi, 110029 India.

Acute graft-versus-host disease (aGVHD) and relapse are major issues for patients undergoing allogenic hematopoietic stem cell transplant (allo-HSCT). T-regulatory (Treg) cells in the donor graft are negatively correlated with the incidence of aGVHD without any impact on relapse. In this study to determine the association of Treg cells with aGVHD in allo-HSCT patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12288-018-01071-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439099PMC
April 2019
1 Read

Individual Immune-Modulatory Capabilities of MSC-Derived Extracellular Vesicle (EV) Preparations and Recipient-Dependent Responsiveness.

Int J Mol Sci 2019 Apr 2;20(7). Epub 2019 Apr 2.

Institute for Transfusion Medicine, University Hospital Essen, 45147 Essen, Germany.

Treatment with extracellular vesicles (EVs) derived from mesenchymal stem/stromal cells (MSCs) have been suggested as novel therapeutic option in acute inflammation-associated disorders due to their immune-modulatory capacities. As we have previously observed differences in the cytokine profile of independent MSC-EV preparations, functional differences of MSC-EV preparations have to be considered. To evaluate the immune-modulatory capabilities of specific MSC-EV preparations, reliable assays are required to characterize the functionality of MSC-EV preparations prior to administration to a patient. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20071642DOI Listing

Long-Term Descemetocele Management With Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE) Treatment.

Eye Contact Lens 2019 Apr 9. Epub 2019 Apr 9.

Department of Ophthalmology, USC Roski Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA.

Purpose: To report a patient with chronic ocular graft versus host disease who achieved long-term stability of a descemetocele using prosthetic replacement of the ocular surface ecosystem (PROSE) treatment.

Methods: Case report and literature review.

Results: A 60-year-old white man, who underwent PROSE treatment 4 years earlier to address severe dry eyes secondary to ocular graft versus host disease, developed a central corneal ulcer that resulted in descemetocele formation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/ICL.0000000000000602DOI Listing

Lessons to Learn From Low-Dose Cyclosporin-A: A New Approach for Unexpected Clinical Applications.

Front Immunol 2019 28;10:588. Epub 2019 Mar 28.

INSERM UMR1163 and CNRS URL 8254, Imagine Institute, Paris, France.

Cyclosporin-A has been known and used for a long time, since its "fast track" approval in the early 80's. This molecule has rapidly demonstrated unexpected immunosuppressive properties, transforming the history of organ transplantation. Cyclosporin's key effect relies on modulation on T-lymphocyte activity, which explains its role in the prevention of graft rejection. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2019.00588
Publisher Site
http://dx.doi.org/10.3389/fimmu.2019.00588DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447662PMC
March 2019
1 Read

Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.

Clin Lymphoma Myeloma Leuk 2019 Mar 23. Epub 2019 Mar 23.

Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine Saga University, Saga, Japan; Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine Saga University, Saga, Japan.

Mogamulizumab, a defucosylated humanized monoclonal antibody against the C-C chemokine receptor 4 (CCR4), has been approved for the treatment of relapsed adult T-cell leukemia/lymphoma (ATL). Compared with conventional chemotherapy, mogamulizumab monotherapy displayed more efficacy in relapsed ATL, making mogamulizumab a promising therapeutic agent. However, mogamulizumab could increase graft-versus-host disease, resulting in poor survival outcome in the allogenic stem cell transplant (allo-SCT) setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.03.004DOI Listing
March 2019
1 Read

ST2/MyD88 Deficiency Protects Mice against Acute Graft-versus-Host Disease and Spares T Regulatory Cells.

J Immunol 2019 Apr 12. Epub 2019 Apr 12.

Indiana University School of Medicine, Indianapolis, IN 46202

Acute graft-versus-host disease (aGVHD) hinders the efficacy of allogeneic hematopoietic cell transplantation (HCT). Plasma levels of soluble membrane-bound ST2 (ST2) are elevated in human and murine aGVHD and correlated to type 1 T cells response. ST2 signals through the adapter protein MyD88. Read More

View Article

Download full-text PDF

Source
http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.1800447
Publisher Site
http://dx.doi.org/10.4049/jimmunol.1800447DOI Listing
April 2019
1 Read

Gene Polymorphism of Tacrolimus-Metabolizing Enzymes Associated With Impaired Absorption of Tacrolimus Following Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.

Transplant Proc 2019 Apr 26;51(3):998-1001. Epub 2019 Jan 26.

Department of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.

Objective: To elucidate the mechanisms by which orally administered tacrolimus was not absorbed in a patient following allogeneic hematopoietic stem cell transplantation.

Clinical Course: A 17-year-old girl with acute myeloid leukemia underwent HLA-haploidentical peripheral blood stem cell transplantation following fludarabine, busulfan, and total-body irradiation. Graft-vs-host disease prophylaxis was post-transplant cyclophosphamide, followed by intravenous tacrolimus and mycophenolate mofetil. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2019.01.061DOI Listing
April 2019
2 Reads

New Strategy of Acute Graft-vs-Host Disease: Investigation of a Reduced Dose of Antithymocyte Globulin in Haploidentical Hematopoietic Stem Cell Transplantation.

Transplant Proc 2019 Apr 9;51(3):890-895. Epub 2019 Jan 9.

Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China. Electronic address:

Graft-vs-host disease (GVHD) is one of the biggest challenges in haploidentical hematopoietic stem cell transplantation. Antithymocyte globulins (ATGs) are widely used to overcome GVHD, but excessive immunosuppression increases the chances of relapse and infection following transplantation. No defined standard of the appropriate dose of ATG usage is recognized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2018.10.028DOI Listing
April 2019
1 Read

Mesenchymal Stem Cells as a Salvage Treatment for Severe Refractory Graft-vs-Host Disease in Children After Bone Marrow Transplantation.

Transplant Proc 2019 Apr 8;51(3):880-889. Epub 2019 Jan 8.

Department of Transplantation, Jagiellonian University Medical College, Krakow, Poland.

Application of mesenchymal stem cells (MSC) enables a novel approach to the therapy of graft- vs-host disease (GVHD) after hematopoietic stem cell transplantation. Herein we present our preliminary experience with the use of allogeneic bone marrow‒derived MSC in 9 pediatric patients after hematopoietic transplantation complicated by severe acute or chronic GVHD (aGVHD, cGVHD) resistant to steroids and second-line immunosuppressants. The MSC therapy was applied concurrently with immunosuppressive treatment in 5 patients as a single infusion, in four patients as 2-6 infusions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2019.01.023DOI Listing
April 2019
1 Read

The impact of severe late-effects after 12 Gy fractionated total body irradiation and allogeneic stem cell transplantation for childhood leukemia (1988-2010).

Pediatr Hematol Oncol 2019 Apr 12:1-17. Epub 2019 Apr 12.

c Host Research Team EA4607 SNA-EPIS, PRES Lyon, Jean Monnet University, University Hospital , Saint-Etienne , France.

This study consists of a retrospective study including 71 childhood leukemia survivors (36 females) treated with allo-HSCT 12 Gy fractionated total body irradiation (fTBI) conditioning, with a median age of 25.0 y at time of follow-up and a median delay of 14.8 y since the graft. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/08880018.2019.1591549DOI Listing
April 2019
1 Read

Clinical features of chronic graft-versus-host disease following haploidentical transplantation combined with infusion of a cord blood.

Stem Cells Dev 2019 Apr 12. Epub 2019 Apr 12.

Department of Respiratory Medicine, the Fifth People's Hospital of Suzhou, Suzhou, China, China ;

Our previous studies demonstrated promising outcomes after haploidentical donor transplant combined with unrelated umbilical cord blood (haplo-cord-HSCT) for hematological disorders. However, clinical profiling regarding chronic graft-versus-host disease (cGVHD) has not yet been fully described under this protocol. This study analyzed the clinical characteristics of cGVHD among 300 patients with hematological malignancies who received haplo-cord-HSCT between January 2012 and July 2016 at our center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/scd.2018.0259DOI Listing
April 2019
1 Read

Killer-cell immunoglobulin-like receptor ligand mismatch cord blood transplantation in high-risk neuroblastoma.

Pediatr Int 2019 Apr 11. Epub 2019 Apr 11.

Department of Pediatrics, Showa University Fujigaoka Hospital, Japan.

Background: The prognosis of high-risk neuroblastoma-stage 4 with bone marrow metastasis, MYCN amplified, or refractory neuroblastoma is poor. To date, no standard treatment has been established. In an attempt to measure the survival rates of four selected cases, we challenged the killer-cell immunoglobulin-like receptor ligand mismatch cord blood transplantation in the graft-versus-host disease with reduced intensity conditioning. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ped.13861DOI Listing
April 2019
1 Read

Feasibility of extracorporeal photopheresis in pediatric patients with graft-versus-host disease after hematopoietic stem cell transplantation.

Pediatr Transplant 2019 Apr 11:e13416. Epub 2019 Apr 11.

The Child and Adolescent Clinic, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

Graft-versus-host disease (GVHD) is a main cause of morbidity and mortality following hematopoietic stem cell transplantation. The cumulative incidence of acute and chronic GVHD (aGVHD, cGVHD) reaches 30%-50% and 20% in pediatric populations, respectively. Prednisolone and/or calcineurin inhibitors (CNI) are first-line treatments, but no superior second-line treatment has yet been established. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/petr.13416DOI Listing
April 2019
2 Reads

Patterns of onset and outcome of cryptogenic organizing pneumonia after allogeneic hematopoietic stem cell transplantation.

Int J Hematol 2019 Apr 10. Epub 2019 Apr 10.

Department of Hematology and Oncology, Konan Kosei Hospital, 137 Omatsubara, Takaya-cho, Konan, Aichi, 483-8704, Japan.

Cryptogenic organizing pneumonia (COP) after allogeneic hematopoietic stem cell transplantation (HSCT) is characterized by frequent recurrence. Few studies have examined onset and recurrence patterns of COP after HSCT. We investigated the clinical features of COP after HSCT in a single-center retrospective study including 165 consecutive patients who underwent allogeneic HSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02643-9DOI Listing
April 2019
1 Read

CD150Treg cells may attenuate graft versus host disease and intestinal cell apoptosis after hematopoietic stem cell transplantation.

Am J Transl Res 2019 15;11(3):1299-1310. Epub 2019 Mar 15.

Department of Hematology, The Third Affiliated Hospital of Chongqing Medical University (Gener Hospital) Chongqing 401120, China.

Combined transplantation of regulatory T cells (Treg cells) may significantly attenuate graft versus host disease (GVHD) after hematopoietic stem cell transplantation (HSCT). Recent studies indicated that CD150+Treg cells could secret adenosine to maintain the quiescent status of HSCs. However, whether it is attributable to the attenuation of GVHD after HSCT is still unclear. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456532PMC
March 2019
1 Read

Clinical versus histological grading in the assessment of cutaneous graft versus host disease.

Eur J Med Res 2019 Apr 10;24(1):19. Epub 2019 Apr 10.

Department of Pathology, University Medical Centre Utrecht, PO box 85500, 3508 GA, Utrecht, The Netherlands.

Background: Skin biopsies are often used in daily practice for the diagnosis of acute (aGvHD) or chronic graft versus host disease (cGvHD). With the latest understanding in pathogenesis and new National Institute of Health (NIH) classifications for aGvHD and cGvHD, there is a need to evaluate the current prognostic value of histological grading cutaneous GvHD and its correlation to the clinical grade.

Methods: In a retrospective study with 120 skin biopsies (all taken for suspected GvHD) from 110 patients (all classified according to the NIH), biopsies were revised and graded, blinded for clinical information, for either acute of chronic features. Read More

View Article

Download full-text PDF

Source
https://eurjmedres.biomedcentral.com/articles/10.1186/s40001
Publisher Site
http://dx.doi.org/10.1186/s40001-019-0377-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457000PMC
April 2019
1 Read

[Pancytopenia of unknown origin in a 52-year-old patient].

Internist (Berl) 2019 Apr 10. Epub 2019 Apr 10.

Klinik für Stammzelltransplantation, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland.

A 52-year-old patient developed pancytopenia of unknown origin 1.5 years after allogeneic stem cell transplantation. The bone marrow aspirate showed visceral leishmaniasis (VL). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00108-019-0596-5
Publisher Site
http://dx.doi.org/10.1007/s00108-019-0596-5DOI Listing
April 2019
3 Reads

Efficacy, toxicity and infectious Complications in Ruxolitinib Treated Patients with Corticosteroid-refractory Graft-versus-host Disease after Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant 2019 Apr 6. Epub 2019 Apr 6.

Blood & Marrow Transplantation and Cellular Therapy Program, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI.

Corticosteroid-refractory GVHD (SR-GVHD) remains a significant source of morbidity after allogeneic hematopoietic cell transplantation (HCT). No standard therapy exists in this setting, however recent studies have demonstrated a very promising role for ruxolitinib, an oral Janus Kinase (JAK) 1/2 inhibitor. With increasing evidence of efficacy for SR-GVHD, limited data exists describing complications of ruxolitinib use, and specifically infectious complications during use in SR-GVHD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.04.003DOI Listing

Neutrophil extracellular traps (NETs) contribute to pathological changes of ocular graft-vs.-host disease (oGVHD) dry eye: Implications for novel biomarkers and therapeutic strategies.

Ocul Surf 2019 Apr 6. Epub 2019 Apr 6.

Cornea Translational Biology Laboratory, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, 60612, USA. Electronic address:

Purpose: To investigate the role of neutrophil extracellular traps (NETs) and NET-associated proteins in the pathogenesis of oGVHD and whether dismantling of NETs with heparin reduces those changes.

Methods: Ocular surface washings from oGVHD patients and healthy subjects were analyzed. Isolated peripheral blood human neutrophils were stimulated to generate NETs and heparinized NETs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtos.2019.03.010DOI Listing

Allogeneic Hematopoietic Stem Cell Transplant Outcomes for Patients with Dominant-Negative IKFZ1/IKAROS Mutations.

J Allergy Clin Immunol 2019 Apr 6. Epub 2019 Apr 6.

Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Allogeneic hematopoietic cell transplantation for patients with dominant-negative IKZF1/IKAROS mutations is not associated with unusually high risks of acute graft versus host disease or mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2019.03.025DOI Listing
April 2019
1 Read

Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation.

Exp Hematol Oncol 2019 28;8. Epub 2019 Mar 28.

1Institute for Advanced Biosciences, Université Grenoble Alpes, INSERM 1209, UMR CNRS 5309, Grenoble, France.

Background: Immune checkpoint inhibitors have radically changed the landscape of anti-tumor therapies in several malignancies. However the adverse events associated with immune checkpoint blockade in combination with other treatments remains to be thoroughly documented. Here we report the case of a 33-year-old male with classical Hodgkin lymphoma who was successfully treated for lymphoma but experienced serious and eventually fatal multisystem organ failure following nivolumab administration and allogeneic stem cell transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40164-019-0132-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437980PMC
March 2019
1 Read

Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis.

Bone Marrow Transplant 2019 Apr 8. Epub 2019 Apr 8.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Ruxolitinib (Rux), a Jak1/2 inhibitor, results in reduced spleen size and improvement in constitutional symptoms in the majority of patients with myelofibrosis (MF). Therefore Rux, when given prior to hematopoietic cell transplantation (HCT) in patients with MF was hypothesized to improve engraftment, decrease incidence and severity of graft-versus-host disease, and lower non-relapse mortality (NRM). We conducted a phase II prospective trial to assess the effects of pre-HCT Rux on post-HCT outcomes in patients with MF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0523-3DOI Listing
April 2019
1 Read

Health Care Utilization is High in Adult Patients Relapsing After Allogeneic Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant 2019 Apr 5. Epub 2019 Apr 5.

Division of Blood and Marrow Transplantation, Department of Medicine, Stanford, CA.

Disease relapse is the leading cause of death for patients with acute leukemia (AL) and myelodyspastic syndrome (MDS) who undergo allogeneic hematopoietic cell transplantation (HCT). Relapse post-HCT is associated with poor prognosis; however, the inpatient health care utilization of this population is unknown. Here we describe survival, intensity of health care utilization, and characteristics associated with high resource utilization at the end-of-life (EOL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.04.001DOI Listing
April 2019
1 Read

Impact of Cyclosporine-A Concentration on Acute Graft-versus-Host Disease Incidence after Haploidentical Hematopoietic Cell Transplantation.

Eur J Haematol 2019 Apr 8. Epub 2019 Apr 8.

Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), F-75012, Paris, France.

Objectives: This retrospective study analyzed the impact of early cyclosporine-A (CsA) initiation (day - 3) on the risk of acute graft-versus-host disease (aGvHD) after haploidentical hematopoietic cell transplantation (Haplo-HCT) using post-transplant cyclophosphamide.

Methods: Sixty-one consecutives patients who underwent Haplo-HCT were analyzed.

Results: At day +180, the cumulative incidences of grade II-IV and grade III-IV aGvHD were 39% and 18%, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13233DOI Listing
April 2019
1 Read

Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanised mouse model of graft-versus-host disease.

Immunol Cell Biol 2019 Apr 7. Epub 2019 Apr 7.

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW, 2252, Australia.

Allogeneic haematopoietic stem cell transplantation (HSCT) is a curative therapy for a number of haematological malignancies, but is limited by the development of graft-versus-host disease (GVHD). CD39 and CD73 form an ecto-enzymatic pathway that hydrolyses extracellular adenosine 5'-triphosphate (ATP) to adenosine, which respectively exacerbate or alleviate disease in allogeneic mouse models of GVHD. The current study aimed to explore the role of the CD39/CD73 pathway and adenosine receptor (AR) blockade in a humanised mouse model of GVHD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/imcb.12251DOI Listing
April 2019
3 Reads

Ruxolitinib for Therapy of Graft-versus-Host Disease.

Biomed Res Int 2019 6;2019:8163780. Epub 2019 Mar 6.

University Medicine Greifswald, Internal Medicine C, Hematology and Oncology, Stem Cell Transplantation and Palliative Care, Ferdinand-Sauerbruch-Strasse, 17475 Greifswald, Germany.

Objective: Steroid-resistant graft-versus-host disease (GvHD) is a major challenge after allogeneic stem cell transplantation and associated with significant morbidity and mortality. There is no therapeutic standard defined beyond calcineurin inhibitors (CNI) and steroids. Furthermore, some patients may have contraindications against CNI or high-dose steroids. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/8163780DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431395PMC

Efficacy of parenteral glutamine supplementation in adult hematopoietic stem cell transplantation patients.

Blood Res 2019 Mar 21;54(1):23-30. Epub 2019 Mar 21.

Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.

Background: Hematopoietic stem cell transplantation (HSCT) patients need parenteral nutrition because of nausea, vomiting, and mucositis caused by conditioning regimens. The demand for glutamine increases during the HSCT period. We evaluated the effects of glutamine-containing parenteral nutrition on the clinical outcomes of HSCT patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5045/br.2019.54.1.23DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439295PMC
March 2019
2 Reads

A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease.

Expert Rev Hematol 2019 Apr 6:1-13. Epub 2019 Apr 6.

f Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre , University of Toronto , Toronto , Canada.

Introduction: Chronic graft-versus-host disease (chronic GVHD) is a leading cause of late death and contributes significantly to morbidity following hematopoietic stem cell transplantation. This study aims to provide a systematic literature review on incidence, mortality, and relapse of chronic GVHD patients. Areas covered: The authors searched for English-language articles published between 2007 and 2017 using PubMed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1605288DOI Listing
April 2019
1 Read

Corrigendum to 'Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease and graft-versus host disease guided multiple DLIs could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractory/relapsed Acute Leukemia' [Biology of Blood and Marrow Transplantation 23/8 (2017) 1311-1319].

Biol Blood Marrow Transplant 2019 Apr 4. Epub 2019 Apr 4.

Peking University Peoples Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China; Collaborative Innovation Center of Hematology, Beijing, China; Nanfang Hospital, Southern Medical University, Beijing, China; Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Beijing, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.006DOI Listing
April 2019
3 Reads

High-resolution HLA phased haplotype frequencies to predict the success of unrelated donor searches and clinical outcome following hematopoietic stem cell transplantation.

Bone Marrow Transplant 2019 Apr 5. Epub 2019 Apr 5.

Transplantation Immunology Unit and National Reference Laboratory for Histocompatibility, Department of Diagnostic, Geneva University Hospitals, Geneva, Switzerland.

HLA matching is a critical factor for successful allogeneic hematopoietic stem cell transplantation. For unrelated donor searches, matching is usually based on high-resolution typing at five HLA loci, looking for a 10/10 match. Some studies have proposed that further matching at the haplotype level could be beneficial for clinical outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0520-6DOI Listing

The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia.

Blood Adv 2019 Apr;3(7):1118-1128

Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.

When hematopoietic stem cell transplant (HSCT) is necessary for children with acute myeloid leukemia (AML), there remains debate about the best stem cell source. Post-HSCT relapse is a common cause of mortality, and complications such as chronic graft versus host disease (cGVHD) are debilitating and life-threatening. To compare post-HSCT outcomes of different donor sources, we retrospectively analyzed consecutive transplants performed in several international centers from 2005 to 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018025908DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457227PMC
April 2019
2 Reads

Unrelated donor peripheral blood stem cell transplantation for patients with β-thalassaemia major based on a novel conditioning regimen.

Biol Blood Marrow Transplant 2019 Apr 2. Epub 2019 Apr 2.

Department of Hematology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, PR China; Department of Pediatric Hematology-Oncology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, PR China. Electronic address:

Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is the only available curative treatment for patients with β-thalassemia major (β-TM). However, the problem of finding a suitable sibling donor (SD) with well-matched human leukocyte antigens (HLAs) is still a major obstacle to curing these patients. With the progress in high-resolution HLA typing technology and supportive care, outcomes after allo-HSCT from a HLA-well-matched unrelated donor (UD) now approach those of well-matched SDs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.028DOI Listing
April 2019
1 Read

Donor-derived CIK Cell Infusion as Consolidation after Non-myeloablative Allogeneic Transplant for Myeloid Neoplasms.

Biol Blood Marrow Transplant 2019 Apr 2. Epub 2019 Apr 2.

Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, CA. Electronic address:

Non-myeloablative conditioning, such as with total lymphoid irradiation and anti-thymocyte globulin (TLI-ATG), has allowed hematopoietic allotransplantation with curative potential for older patients and those with comorbid medical conditions with myeloid neoplasms. However, early achievement of full donor chimerism (FDC) and relapse remain challenges. Cytokine induced killer (CIK) cells have been shown to have anti-tumor cytotoxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.027DOI Listing
April 2019
1 Read